Enabled Therapeutics

Enabled Therapeutics is a private, preclinical-stage biotech leveraging its proprietary Capton® platform to create precision neurology therapeutics. Its core innovation involves engineering prodrugs that are activated specifically in diseased brain tissue by the unique biochemical environment of neuropathology, aiming to minimize off-target effects and improve efficacy. The company has gained FDA alignment for its lead candidate, CPT-021, in Alzheimer's disease and is building its leadership team to advance its pipeline. Enabled Therapeutics represents a novel approach to CNS drug delivery, targeting a significant unmet medical need in neurodegeneration.

Capton® platform: A redox-activated prodrug technology that engineers small molecules to be blood-brain barrier penetrant and selectively activated only in diseased brain tissue by elevated transition metals and reactive oxygen species, minimizing off-target effects.

Enabled Therapeutics competes in the crowded neurodegenerative disease space against large pharma (e.g., Biogen, Eli Lilly) and numerous biotechs. Its key differentiation is its site-specific activation mechanism, which aims for superior precision and safety compared to broadly active small molecules or invasive biologics. It competes with other targeted delivery approaches, but its redox-activation chemistry is unique.